Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Locus-coeruleus-funksjon hos normale eldre og AD-risiko (LEAD)

4. november 2026 oppdatert av: NYU Langone Health

Growing evidence suggests that Alzheimer's disease (AD) pathological changes begin decades before clinical symptoms and tau abnormalities in the locus coeruleus (LC) can be observed since midlife. We have previously demonstrated functional vulnerability of the LC to aging and stress, as well as an association between higher cerebrospinal fluid (CSF) tau and impaired sleep phenomena influenced by the LC. We now aim to test whether LC dysfunction can be measured in preclinical AD stages by LC targeted imaging, and whether it objectively affects sleep architecture and attention. We will test this hypothesis in 30 cognitively normal older adults by performing a full clinical evaluation, one night of polysomnography, a lumbar puncture to obtain cerebrospinal fluid, [11C]MRB PET-MR, and attention testing. This study has the potential to identify a new mechanism by which tau pathology contributes to sleep and attention dysfunction and may provide a new therapeutic target for AD prevention.

Studieoversikt

Detaljert beskrivelse

The purpose of this study is three-fold: to test whether lower NET availability in the LC is associated with: first, CSF tau levels typical of preclinical stages of AD (Aim 1); second, reduced REM and spindle density (Aim 2); and third, impaired performance on attention tasks (Aim 3). The goal is to test the overarching hypothesis that LC dysfunction occurs in preclinical AD stages, can be measured with MRB-PET, and translates into impairment of sleep architecture (LC tonic dysfunction) and attention (LC phasic dysfunction).

Studietype

Intervensjonell

Registrering (Faktiske)

34

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • New York
      • New York, New York, Forente stater, 10029
        • Icahn School of Medicine Mount Sinai
      • New York, New York, Forente stater, 10016
        • NYU Grossman School of Medicine

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

55 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Male and female subjects with normal cognition and 55-75 years of age will be enrolled.
  • Subjects will be within normal limits on neurological and psychiatric examinations.
  • All subjects enrolled will have a CDR of 0. This will be evaluated through a clinical interview administered by a study physician (informant interview will not be required).
  • All subjects will have had a minimum of 12 years of education.

Exclusion Criteria:

  • History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, stroke, mental retardation or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders).
  • Significant history of alcoholism or drug abuse.
  • Significant history of psychiatric illness (e.g., schizophrenia, bipolar, PTSD, or life-long history of major depression).
  • Geriatric Depression Scale (short form)>6.
  • Insulin dependent diabetes.
  • Evidence of clinically relevant cardiac, pulmonary, endocrine or hematological conditions.
  • Physical impairment of such severity as to adversely affect the validity of psychological testing.
  • Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging.
  • History of a first-degree family member with early onset (age <60 years) dementia.
  • Irregular sleep-wake rhythms (based on the actigraphy recordings) or significant OSA (AHI4%≥15).
  • Taking Coumadin/warfarin and/or medications affecting cognition or sleep.
  • Failure to complete all study visit within 4 months

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Kognitivt normale (CN) eldre voksne

Nocturnal polysomnography (NPSG) to measure REM sleep and sleep spindles characteristics.

Lumbar puncture (LP) to measure CSF P-Tau, T-Tau and Aβ42/40 ratio.

PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]O-methylreboxetine ([11C]MRB) to measure NET availability.

Psychomotor vigilance task (PVT) and the OddBall to measure test taskattention performance.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Methylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) Values
Tidsramme: Visit 4 (1-4 weeks after LP that occurred on day 14)
Visit 4 (1-4 weeks after LP that occurred on day 14)
Total Rapid Eye Movement (REM) Duration (Min)
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of Time Spent in REM Sleep
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Less Than 5 Minutes
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Greater Than or Equal to 5 Minutes
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Greater Than or Equal to 10 Minutes
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of Correct Responses on the Picture Test
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Number of Sleep Spindles That Occur Per Minute During the N2 Stage of Sleep (N2 Spindle Density)
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

N2 Spindle Density is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Mean Psychomotor Vigilance Test (PVT) Reaction Time
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

PVT measures the reaction speed to a randomly time-occuring visual stimuli, allowing the assessment of several aspects of attention including response times, attention lapses and false starts.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Picture Test Response Time
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Levels of Hyperphosphorylated Tau (P-Tau)
Tidsramme: Visit 4 (1-4 weeks after LP that occurred on day 14)

Levels will be derived from the plasma and reported in pg/mL

Visit 4 (1-4 weeks after LP that occurred on day 14)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Ricardo Osorio, NYU Langone Health

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

6. august 2020

Primær fullføring (Faktiske)

26. mars 2024

Studiet fullført (Faktiske)

26. mars 2024

Datoer for studieregistrering

Først innsendt

21. mai 2020

Først innsendt som oppfylte QC-kriteriene

21. mai 2020

Først lagt ut (Faktiske)

27. mai 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

All of the individual participant data collected during the trial, after deidentification.

IPD-delingstidsramme

Immediately following publication. No end date.

Tilgangskriterier for IPD-deling

The investigator who proposed to use the ricardo.osorio@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere